West Nile FeverPhase 1NCT00300417
Phase I Study of West Nile Virus Vaccine
A Phase 1 study testing VRC-WNVDNA020-00-VP in people with West Nile Fever, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in United States.
Trial summary
This study will test the safety of an experimental vaccine for preventing West Nile virus infection. The virus is spread mainly by mosquito bites. Symptoms can include high fever, headache, neck stiffness, stupor, muscle weakness, vision loss, numbness and paralysis. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- West Nile Fever
- What is being tested?
- VRC-WNVDNA020-00-VP
- How many people
- 30 participants
- Where
- 1 siteUnited States
- Study dates
- 3 Mar 2006to 28 Dec 2007
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- A participant must meet all of the following criteria:
- 18 to 65 years old.
- Available for clinical follow-up through Week 32 and contact (correspondence, telephone or e-mail) or clinical visit through Week 52 of the study.
- Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
- Complete an Assessment of Understanding prior to enrollment and verbalize understanding of all questions answered incorrectly.
- Able and willing to complete the informed consent process.
Show all 37Show fewer
- Willing to receive HIV test results and willing to abide by NIH guidelines for partner notification of positive HIV results.
- Willing to donate blood for sample storage to be used for future research and genetic testing, including HLA analysis.
- In good general health without clinically significant medical history and has satisfactorily completed screening.
- Physical examination and laboratory results without clinically significant findings and a body mass index (BMI) less than 40 within the 28 days prior to enrollment.
- Laboratory Criteria within 28 days prior to enrollment:
- Hemoglobin greater than or equal to 11.5 g/dL for women; greater than or equal to 13.5 g/dL for men.
- White blood cell (WBC) equal to 3,300-12,000 cells/mm(3).
- Absolute neutrophil count (ANC) within institutional normal range.
- Total lymphocyte count greater than or equal to 800 cells/mm(3).
- Platelets equal to 125,000 - 400,000/mm(3).
- Alanine aminotransferase (ALT; SGPT) less than or equal to 1.25 x upper limit of normal.
- Serum creatinine less than or equal to 1 x upper limit of normal (less than or equal to 1.3 mg/dL for females; less than or equal to 1.4 mg/dL for males).
- Normal urinalysis defined as negative glucose, negative or trace protein, and no clinically significant blood in the urine.
- Negative FDA-approved HIV blood test. [Note: Results of HIV ELISA will be documented, but a negative HIV PCR will be sufficient for eligibility screening of subjects with positive HIV ELISA that is due to prior participation in an HIV vaccine study.]
- Negative hepatitis B surface antigen.
- Negative anti-HCV and negative hepatitis C virus (HCV) PCR.
- Laboratory Criteria within 12 weeks (84 days) prior to enrollment:
- Negative flavivirus serology (in the Focus Technologies WNV antibody ELISA assay) within 84 days prior to enrollment and no history of prior vaccination against yellow fever or Japanese encephalitis virus; and no history of prior vaccination against West Nile virus with an investigational vaccine.
- Female-Specific Criteria:
- Negative beta-HCG pregnancy test (urine or serum) on day of enrollment for women presumed to be of reproductive potential.
- A female participant must meet any of the following criteria:
- No reproductive potential because of menopause (one year without menses) or because of a hysterectomy, bilateral oophorectomy, or tubal ligation,
- or
- Participant agrees to be heterosexually inactive at least 21 days prior to enrollment and through Week 32 of the study,
- or
- Participant agrees to consistently practice contraception at least 21 days prior to enrollment and through Week 32 of the study by one of the following methods:
- condoms, male or female, with or without a spermicide
- diaphragm or cervical cap with spermicide
- intrauterine device
- contraceptive pills or patch, Norplant, Depo-Provera or other FDA-approved contraceptive method
- male partner has previously undergone a vasectomy
Who cannot join
- A volunteer will be excluded if one or more of the following conditions apply.
- Women:
- Breast-feeding or planning to become pregnant during the 32 weeks of study participation.
- Volunteer has received any of the following substances:
- Immunosuppressive medications, cytotoxic medications, inhaled corticosteroids, or long-acting beta-agonists within the past six months. (Note that use of corticosteroid nasal spray for allergic rhinitis, topical corticosteroids for an acute uncomplicated dermatitis, or short-acting beta-agonists in controlled asthmatics are not excluded).
- Blood products within 120 days prior to HIV screening.
Show all 34Show fewer
- Immunoglobulin within 60 days prior to HIV screening.
- Investigational research agents within 30 days prior to initial study vaccine administration.
- Live attenuated vaccines within 30 days prior to initial study vaccine administration.
- Medically indicated subunit or killed vaccines, e.g. influenza, pneumococcal, or allergy treatment with antigen injections, within 14 days of study vaccine administration.
- Current anti-TB prophylaxis or therapy.
- Volunteer has a history of any of the following clinically significant conditions:
- Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain.
- Autoimmune disease or immunodeficiency.
- Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that requires the use of oral or intravenous corticosteroids.
- Diabetes mellitus (type I or II), with the exception of gestational diabetes.
- History of thyroidectomy or thyroid disease that required medication within the past 12 months.
- Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years.
- Hypertension that is not well controlled by medication or is more than 145/95 at enrollment.
- Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws.
- Malignancy that is active or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of the study.
- Seizure disorder other than: 1) febrile seizures under the age of two, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) a singular seizure not requiring treatment within the last 3 years.
- Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen.
- Allergic reaction to aminoglycoside antibiotics.
- Psychiatric condition that precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder; disorder requiring lithium; or within five years prior to enrollment, a history of suicide plan or attempt.
- Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent.
- Active smoker within the past 5 years AND with 25 pack-years or greater smoking history.
- If age 51-65 years and with 3 or more of the 5 health risk factors noted below, the subject will be excluded:
- Current smoker (or quit smoking less than 28 days prior to enrollment)
- BMI greater than 35
- Fasting low density lipoprotein (LDL) greater than 159 mg/dL or fasting cholesterol greater than 239 mg/dL
- Systolic blood pressure greater than 140 mm Hg or diastolic blood pressure greater than 90 mm Hg
- Fasting blood glucose greater than 125 mg/dL
- Note: The fasting blood tests require 8 hours fast prior to the blood draw. The results used for eligibility screening must be from tests completed no more than 12 weeks (84 days) prior to day of enrollment. The individual criteria for BMI (inclusion item 9), blood pressure (exclusion item 15) and smoking history (exclusion item 23) must also be met.
Trial locations and contacts
1 site in 1 country.
United States1 site
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892
About this study
Official title: A Phase I Study of the Safety and Immunogenicity of a West Nile Virus Recombinant DNA Plasmid Vaccine, VRC-WNVDNA020-00-VP, in Healthy Adult Subjects
This study will test the safety of an experimental vaccine for preventing West Nile virus infection. The virus is spread mainly by mosquito bites. Symptoms can include high fever, headache, neck stiffness, stupor, muscle weakness, vision loss, numbness and paralysis. Rarely, infection leads to permanent nerve damage and possibly death. The vaccine used in the study is made from DNA that codes for West Nile virus proteins. Injected into a muscle, the DNA instructs the body to make a small amount of West Nile virus protein. This study will see if the body creates resistance or immunity to these proteins. Participants cannot get West Nile virus from the vaccine.
Healthy normal volunteers between 18 and 65 years of age may be eligible for this study. Candidates are screened with a medical history, physical examination, and blood and urine tests for various infections and other medical problems. Women who are able to become pregnant are given a pregnancy test. Women who are pregnant or breastfeeding may not participate. Anyone who has received a vaccination for Yellow Fever or Japanese Encephalitis virus in the past may not participate in this research study.
Read more
Participants will receive three injections of the experimental vaccine, the first on the first study day (Day 0), the second on Day 28, and the third on Day 56. The injections are given with a device called Biojector® (Registered Trademark) 2000 that delivers the vaccine through the skin into the muscle without the use of a needle. On the day of each injection, subjects are given a diary card to take home for recording their temperature and any symptoms or side effects for 5 days. They return to the clinic 2 weeks after each injection, bringing the completed card with them at that time. In addition to the injections, subjects have the following tests and procedures during clinic visits:
- Medical history and, if needed, physical examination: Day 0 and weeks 2, 4, 6, 8, 10, 12, 24 and 32
- Vital signs and weight: Day 0 and weeks 2, 4, 6, 8, 10, 12, 24 and 32
- Lymph node exam: Day 0 and weeks 2, 4, 6, 8, 10, and 12
- Blood samples: Day 0 and weeks 2, 4, 6, 8, 10, 12, 24 and 32
- Pregnancy test (for women): Day 0 and weeks 4, 8 and 32
- Urine sample: Day 0 and weeks 2, 4, 6, 8, and 10
The blood and urine tests are for health checks. Some blood samples are also used to study the immune response to the vaccine and for gene testing.
Read the detailed description
Study Design: This is a Phase I open-label study to evaluate safety, tolerability, and immunogenicity of a recombinant DNA vaccine, VRC-WNVDNA020-00-VP. The hypothesis is that this regimen will be safe for human administration and elicit a higher titer of neutralizing antibody response than a prior WNV DNA vaccine. The primary objectives are to evaluate the safety and tolerability in humans of the investigational vaccine in healthy young adults and in healthy older adults. Secondary and exploratory objectives are related to the immunogenicity of the study vaccine.
Product Description: VRC-WNVDNA020-00-VP is composed of a single closed-circular DNA plasmid that encodes the WNV viral protein precursor transmembrane (prM) and envelope (E) with a CMV/R promoter. Vaccine vials will be supplied at 4 mg/mL. Each DNA vaccination will be 1 mL of vaccine administered intramuscularly (IM) in the deltoid muscle using the Biojector 2000 Needle-Free Injection Management System (Biojector).
Subjects: A total of 30 healthy adults will be enrolled in two groups: Group 1 will be comprised of 15 healthy adults 18 to 50 years old and Group 2 will be comprised of 15 healthy adults 51 to 65 years old.
Study Plan: All subjects will receive 3 injections on the schedule shown in the schema. The protocol requires nine clinic visits and three telephone follow-up contacts.
Study Duration: 32 weeks of clinical follow up for each participant. A long-term follow-up contact at Week 52 may include interim medical history and research blood draw; or subject may opt for the long-term contact to occur by telephone, e-mail or mail for the interim medical history only.
Study Endpoints: The primary endpoint is safety and tolerability of the regimen. The secondary immunogenicity endpoints are WNV neutralizing antibody, WNV specific antibody as measured by ELISA, WNV-specific T cell responses measured by intracellular cytokine staining (ICS) assay and ELISPOT. Other immunogenicity assays through Week 32 may also be completed as exploratory evaluations, as well as from the Week 52 blood samples if collected.
- Conditions
- West Nile Fever
- Being tested
- VRC-WNVDNA020-00-VP
- Keywords
- Flavivirus, Mosquito, Immunity, Preventive, West Nile Fever, West Nile Virus, Vaccine, Healthy Volunteer, HV
- Medical subject headings
- West Nile Fever
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VRC-WNVDNA020-00-VPDrug
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Mar 2006 (estimated)
- Study start3 Mar 2006
- Study completion28 Dec 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for West Nile FeverStudies of the same condition, open and under way.
- More trials run by National Institute of Allergy and Infectious Diseases (NIAID)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Enrolment
- 30 participants
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00300417
- Sponsor's protocol ID
- 060110
- Other IDs
- 06-I-0110
- Status last verified
- 28 Dec 2007
- First submitted
- 7 Mar 2006
- Last updated
- 2 Jul 2017
- Results posted
- No
Publications
Centers for Disease Control and Prevention (CDC). West Nile virus activity--United States, September 29-October 5, 2004. MMWR Morb Mortal Wkly Rep. 2004 Oct 8;53(39):922-3.
PubMed 15470326Ledgerwood JE, Pierson TC, Hubka SA, Desai N, Rucker S, Gordon IJ, Enama ME, Nelson S, Nason M, Gu W, Bundrant N, Koup RA, Bailer RT, Mascola JR, Nabel GJ, Graham BS; VRC 303 Study Team. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis. 2011 May 15;203(10):1396-404. doi: 10.1093/infdis/jir054. Epub 2011 Mar 11.
PubMed 21398392
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I Study of the Safety and Immunogenicity of a West Nile Virus Recombinant DNA Plasmid Vaccine, VRC-WNVDNA020-00-VP, in Healthy Adult Subjects
- ClinicalTrials.gov ID
- NCT00300417
- Acronym / sponsor ID
- 060110
- Conditions
- West Nile Fever
- Keywords
- Flavivirus, Mosquito, Immunity, Preventive, West Nile Fever, West Nile Virus, Vaccine, Healthy Volunteer
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)US National Institutes of Health
- Study start
- 3 Mar 2006
- Study completion
- 28 Dec 2007
- First posted
- 8 Mar 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will test the safety of an experimental vaccine for preventing West Nile virus infection. The virus is spread mainly by mosquito bites. Symptoms can include high fever, headache, neck stiffness, stupor, muscle weakness, vision loss, numbness and paralysis. Rarely, infection leads to permanent nerve damage and possibly death. The vaccine used in the study is made from DNA that codes for West Nile virus proteins. Injected into a muscle, the DNA instructs the body to make a small amount of West Nile virus protein. This study will see if the body creates resistance or immunity to these proteins. Participants cannot get West Nile virus from the vaccine.
Healthy normal volunteers between 18 and 65 years of age may be eligible for this study. Candidates are screened with a medical history, physical examination, and blood and urine tests for various infections and other medical problems. Women who are able to become pregnant are given a pregnancy test. Women who are pregnant or breastfeeding may not participate. Anyone who has received a vaccination for Yellow Fever or Japanese Encephalitis virus in the past may not participate in this research study.
Participants will receive three injections of the experimental vaccine, the first on the first study day (Day 0), the second on Day 28, and the third on Day 56. The injections are given with a device called Biojector® (Registered Trademark) 2000 that delivers the vaccine through the skin into the muscle without the use of a needle. On the day of each injection, subjects are given a diary card to take home for recording their temperature and any symptoms or side effects for 5 days. They return to the clinic 2 weeks after each injection, bringing the completed card with them at that time. In addition to the injections, subjects have the following tests and procedures during clinic visits:
- Medical history and, if needed, physical examination: Day 0 and weeks 2, 4, 6, 8, 10, 12, 24 and 32
- Vital signs and weight: Day 0 and weeks 2, 4, 6, 8, 10, 12, 24 and 32
- Lymph node exam: Day 0 and weeks 2, 4, 6, 8, 10, and 12
- Blood samples: Day 0 and weeks 2, 4, 6, 8, 10, 12, 24 and 32
- Pregnancy test (for women): Day 0 and weeks 4, 8 and 32
- Urine sample: Day 0 and weeks 2, 4, 6, 8, and 10
The blood and urine tests are for health checks. Some blood samples are also used to study the immune response to the vaccine and for gene testing.
Detailed description
Study Design: This is a Phase I open-label study to evaluate safety, tolerability, and immunogenicity of a recombinant DNA vaccine, VRC-WNVDNA020-00-VP. The hypothesis is that this regimen will be safe for human administration and elicit a higher titer of neutralizing antibody response than a prior WNV DNA vaccine. The primary objectives are to evaluate the safety and tolerability in humans of the investigational vaccine in healthy young adults and in healthy older adults. Secondary and exploratory objectives are related to the immunogenicity of the study vaccine.
Product Description: VRC-WNVDNA020-00-VP is composed of a single closed-circular DNA plasmid that encodes the WNV viral protein precursor transmembrane (prM) and envelope (E) with a CMV/R promoter. Vaccine vials will be supplied at 4 mg/mL. Each DNA vaccination will be 1 mL of vaccine administered intramuscularly (IM) in the deltoid muscle using the Biojector 2000 Needle-Free Injection Management System (Biojector).
Subjects: A total of 30 healthy adults will be enrolled in two groups: Group 1 will be comprised of 15 healthy adults 18 to 50 years old and Group 2 will be comprised of 15 healthy adults 51 to 65 years old.
Study Plan: All subjects will receive 3 injections on the schedule shown in the schema. The protocol requires nine clinic visits and three telephone follow-up contacts.
Study Duration: 32 weeks of clinical follow up for each participant. A long-term follow-up contact at Week 52 may include interim medical history and research blood draw; or subject may opt for the long-term contact to occur by telephone, e-mail or mail for the interim medical history only.
Study Endpoints: The primary endpoint is safety and tolerability of the regimen. The secondary immunogenicity endpoints are WNV neutralizing antibody, WNV specific antibody as measured by ELISA, WNV-specific T cell responses measured by intracellular cytokine staining (ICS) assay and ELISPOT. Other immunogenicity assays through Week 32 may also be completed as exploratory evaluations, as well as from the Week 52 blood samples if collected.
Study design
- Primary purpose
- Treatment
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (37 listed)
- 18 to 65 years old.
- Available for clinical follow-up through Week 32 and contact (correspondence, telephone or e-mail) or clinical visit through Week 52 of the study.
- Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
- Complete an Assessment of Understanding prior to enrollment and verbalize understanding of all questions answered incorrectly.
- Able and willing to complete the informed consent process.
Key exclusion criteria (34 listed)
- A volunteer will be excluded if one or more of the following conditions apply.
- Breast-feeding or planning to become pregnant during the 32 weeks of study participation.
- Immunosuppressive medications, cytotoxic medications, inhaled corticosteroids, or long-acting beta-agonists within the past six months. (Note that use of corticosteroid nasal spray for allergic rhinitis, topical corticosteroids for an acute uncomplicated dermatitis, or short-acting beta-agonists in controlled asthmatics are not excluded).
- Blood products within 120 days prior to HIV screening.
- Immunoglobulin within 60 days prior to HIV screening.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VRC-WNVDNA020-00-VP | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2017.
- Background: PubMed 15470326Centers for Disease Control and Prevention (CDC). West Nile virus activity--United States, September 29-October 5, 2004. MMWR Morb Mortal Wkly Rep. 2004 Oct 8;53(39):922-3.
- Derived from this study: PubMed 21398392Ledgerwood JE, Pierson TC, Hubka SA, Desai N, Rucker S, Gordon IJ, Enama ME, Nelson S, Nason M, Gu W, Bundrant N, Koup RA, Bailer RT, Mascola JR, Nabel GJ, Graham BS; VRC 303 Study Team. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis. 2011 May 15;203(10):1396-404. doi: 10.1093/infdis/jir054. Epub 2011 Mar 11.
Related trials for West Nile Fever
RecruitingObservational study
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Dengue, Chikungunya
RecruitingPhase 2
High-Titer Neutralizing Plasma for West Nile Fever in Hospitalized Patients
West Nile Fever
Not yet recruiting
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
Leishmaniasis, Leptospirosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing VRC-WNVDNA020-00-VP in people with West Nile Fever, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 37 inclusion and 34 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Jul 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00300417, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2017.